Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsing- Remitting Multiple Sclerosis”

Showing 20 of 0 results

Post-approval studies (Phase 4)Study completedNCT02419378
What this trial is testing

Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
University Hospital Muenster 15
Not applicableLooking for participantsNCT07230015
What this trial is testing

Combined Motor Imagery and Vestibular Rehab for MS

Who this might be right for
Multiple Sclerosis (MS) - Relapsing-remitting
Medipol University 30
Large-scale testing (Phase 3)Looking for participantsNCT07321093
What this trial is testing

The Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis (RRMS)
Biocad 292
Testing effectiveness (Phase 2)Study completedNCT01093326
What this trial is testing

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Actelion 353
Not applicableEnded earlyNCT02949908
What this trial is testing

MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)

Who this might be right for
Multiple Sclerosis
Merck KGaA, Darmstadt, Germany 2
Early research (Phase 1)Study completedNCT02601885
What this trial is testing

A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
AbbVie 20
Early research (Phase 1)Study completedNCT00837785
What this trial is testing

A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Biogen 48
Early research (Phase 1)Study completedNCT05181215
What this trial is testing

Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Banner Life Sciences LLC 46
Testing effectiveness (Phase 2)Study completedNCT00525668
What this trial is testing

Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Charite University, Berlin, Germany 120
Post-approval studies (Phase 4)Study completedNCT01842191
What this trial is testing

Efficacy of Fish Oil in Multiple Sclerosis

Who this might be right for
Relapsing- Remitting Multiple Sclerosis
Coordinación de Investigación en Salud, Mexico 50
Testing effectiveness (Phase 2)UnknownNCT02369926
What this trial is testing

Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Transparency Life Sciences 20
Large-scale testing (Phase 3)Active Not RecruitingNCT06700343
What this trial is testing

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Who this might be right for
Relapsing-remitting Multiple Sclerosis (RRMS)
Amgen 152
Testing effectiveness (Phase 2)Study completedNCT01279876
What this trial is testing

Melatonin in Relapsing-Remitting Multiple Sclerosis Patients

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Tehran University of Medical Sciences 25
Testing effectiveness (Phase 2)Study completedNCT01051817
What this trial is testing

POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler

Who this might be right for
Relapsing-remitting Multiple SclerosisRRMS
Novartis Pharmaceuticals 73
Large-scale testing (Phase 3)Study completedNCT05028634
What this trial is testing

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Celgene 63
Post-approval studies (Phase 4)Study completedNCT02064816
What this trial is testing

Rebif® in Subjects With Relapsing Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany 200
Not applicableEnded earlyNCT01905527
What this trial is testing

Adherence Trial With MS LifeLines ® Services

Who this might be right for
Multiple SclerosisRelapsing-Remitting
EMD Serono 306
Post-approval studies (Phase 4)Active Not RecruitingNCT05296161
What this trial is testing

B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Amsterdam UMC, location VUmc 296
Not applicableStudy completedNCT07346924
What this trial is testing

Effect of Probiotics on Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis (MS) Relapsing Remitting
Cairo University 60
Not applicableStudy completedNCT04280484
What this trial is testing

Acute Intermittent Hypoxia in Persons With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Shirley Ryan AbilityLab 10
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation